ARQT - Company ID 0001787306
The table below shows Arcutis Biotherapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $376.07M | $196.54M | $59.61M | $3.69M | $0.00 | $0.00 |
| Cost of revenue | $36.70M | $19.13M | $4.99M | $754.00K | $0.00 | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $77.05M | $76.42M | $110.58M | $182.44M | $145.56M | $115.31M |
| SG&A |
Arcutis Biotherapeutics, Inc. reported annual revenue of $376.07M for fiscal year 2025. That is up 91.3% from $196.54M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $274.55M |
| $229.39M |
| $185.15M |
| $122.12M |
| $60.97M |
| $21.34M |
| Operating income | -$12.23M | -$128.40M | -$241.10M | -$301.63M | -$206.53M | -$136.65M |
| Income tax | $1.17M | $647.00K | $3.11M | $0.00 | $0.00 | $0.00 |
| Net income | -$16.14M | -$140.04M | -$262.14M | -$311.46M | -$206.36M | -$135.68M |
| EPS (diluted) | -$0.13 | -$1.16 | -$3.78 | -$5.66 | -$4.18 | -$3.80 |